Results 11 to 20 of about 17,815 (221)

The Effect of Ocrelizumab on Anti-JC Virus Antibody Index. [PDF]

Brain Behav
Synopsis: This study of 553 MS patients found that anti‐JC virus (JCV) antibody indices remain stable during the first 2 years of ocrelizumab treatment. While peripheral B‐cells were significantly depleted and serum immunoglobulins (IgG, IgM, IgA) showed modest declines, the JCV antibody index did not change significantly.
Virupakshaiah A, Gill AJ, Schoeps VA, Wilson E, Wilson J, Do D, Bar-Or A, Jacobs D, Berger JR.   +8 more
europepmc   +2 more sources

Clinical and Radiological Characterization of Progressive Multifocal Leukoencephalopathy in HIV-Infected Patients: A Retrospective Analysis and Review of the Literature

Acta Médica Portuguesa, 2015
Introduction: Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system caused by John Cunningham virus, mostly associated with immunodeficiency conditions, such as the human immunodeficiency virus infection ...
Luís Augusto, Nélia Neves, Carina Reis, Cândida Abreu, António Sarmento   +4 more
doaj   +1 more source

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Emerging Infectious Diseases, 2022
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment.
Nicolas Lambert, Solène Dauby, Dominique Dive, Bernard Sadzot, Pierre Maquet   +4 more
doaj   +1 more source

Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate [PDF]

, 2015
BACKGROUND: Progressive multifocal leukoencephalopathy is a severe demyelinating disease caused by the polyoma JC virus in patients with reduced immunocompetence.
Antje Bornemann, Felix Bischof, Nele Dammeier, Till-Karsten Hauser, Victoria Schubert   +4 more
core   +1 more source

Progressive multifocal leukoencephalopathy [PDF]

Current Neurology and Neuroscience Reports, 2000
Progressive multifocal leukoencephalopathy (PML) was a rare disease until the advent of the HIV/AIDS pandemic. Recent interest in the disorder has been spurred by its appearance in patients treated with the monoclonal antibodies natalizumab and rituximab.
openaire   +5 more sources

Progressive Multifocal Leukoencephalopathy [PDF]

F1000Research, 2015
Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease with significant morbidity and mortality and no effective, targeted therapies. It is most often observed in association with abnormalities of cell-mediated immunity, in particular human immunodeficiency virus (HIV) infection, but also occurs in association with ...
Adang, Laura, Berger, Joseph
openaire   +2 more sources

JC Polyomavirus, progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: a review

AIDS Research and Therapy, 2020
The human neurotropic virus JC Polyomavirus, a member of the Polyomaviridae family, is the opportunistic infectious agent causing progressive multifocal leukoencephalopathy, typically in immunocompromised individuals.
Vijay Harypursat, Yihong Zhou, Shengquan Tang, Yaokai Chen   +3 more
doaj   +1 more source

A programme for risk assessment and minimisation of progressive multifocal leukoencephalopathy developed for vedolizumab clinical trials [PDF]

, 2018
Introduction Over the past decade, the potential for drug-associated progressive multifocal leukoencephalopathy (PML) has become an increasingly important consideration in certain drug development programmes, particularly those of immunomodulatory ...
Berger, Joseph R, Clifford, David B, Fox, Irving, Lev, Michael H, Major, Eugene, McAuliffe, Megan, Milch, Catherine, Parikh, Asit, Patti, Mark, Provenzale, James M, Sankoh, Serap, Shick, Jesse, Stephens, Kristin   +12 more
core   +3 more sources

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy [PDF]

, 2006
Background: Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had developed in any other treated patients.
Barkhof, F., Clifford, D.B., Curfman, B., Fahle, G., Fischer, S., Habil, M., Hou, J., Jäger, H.R., Major, E.O., Miszkiel, K., Mueller-Lenke, N., Radue, E.-W., Ryschkewitsch, C., Sanchez, E., Yousry, T.A.   +14 more
core   +1 more source

Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature

Journal of Medical Case Reports, 2018
Background We report the development of asymptomatic progressive multifocal leukoencephalopathy in a patient with multiple sclerosis on natalizumab therapy.
Yinan Zhang, Crystal Wright, Angela Flores   +2 more
doaj   +1 more source